Rapport Therapeutics (RAPP) Total Non-Current Liabilities (2023 - 2024)
Rapport Therapeutics (RAPP) reported Total Non-Current Liabilities of $74000.0 for Q4 2024, down 99.28% year-over-year from $10.3 million in Q1 2024, and down 99.28% quarter-over-quarter from $10.3 million in Q4 2023.
Rapport Therapeutics (RAPP) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Rapport Therapeutics (RAPP) has 2 years of Total Non-Current Liabilities data on file, last reported at $74000.0 in Q4 2024.
- Total Non-Current Liabilities for Q4 2024 came in at $74000.0, down 99.28% year-over-year; the trailing twelve-month figure through Dec 2024 was $74000.0 (down 99.28% YoY), and the FY2024 annual result was $74000.0, down 99.28% from the prior year.
- Total Non-Current Liabilities declined to $74000.0 in Q4 2024 per RAPP's latest filing, from $10.3 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $10.3 million in Q4 2023 and troughed at $74000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 74,000.00 |
| Dec 31, 2023 | 10.28 Mn |